We use cookies to give you the best online experience. By using our website you agree to our use of cookies in accordance with our cookie policy. Learn more

Link to third party site

The link you have selected will take you away from this site to one that is not owned or controlled by Roche, F. Hoffmann-La Roche Ltd makes no representation as to the accuracy of the information contained on sites we do not own or control. Roche does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.

364 Search Results

Spotlight on Emicizumab in the Management of Hemophilia A: Patient Selection and Special Considerations

Yada K and Nogami K. J Blood Med 2019;10:171–181.

Recurrent intracranial bleed in a child receiving prophylaxis with emicizumab

Teo HKW, Wong WH, Lam JCM. Haemophilia. 2021 May;27(3):e415-e418.

Emicizumab, a humanized bispecific antibody to coagulation factors IXa and X with a factor VIIIa-cofactor activity

Kitazawa T, Shima M. Int J Hematol. 2020;111:20–30.

Emicizumab Improves Ex Vivo Clotting Function in Patients with Mild/Moderate Hemophilia A.

Nakajima Y, Nogami K, Yada K, et al. Thromb Haemost 2020;120:968–976.

Cost-effectiveness of emicizumab vs bypassing agents in the prevention of bleeding episodes in haemophilia A patients with anti-FVIII inhibitors in France

Polack B, Trossaërt M, Cousin M, et al. Haemophilia. 2021 Jan;27(1):e1-e11.

Thromboelastometry detects enhancement of coagulation in blood by emicizumab via intrinsic pathway

Szanto T, Vaide I, Jouppila A, et al. Haemophilia. 2021 Jul;27(4):e571-e574

Characterization of the neutralizing anti-emicizumab antibody in a patient with hemophilia A and inhibitor

Valsecchi C, Gobbi M, Beeg M et al. J Thromb Haemost. 2021 Mar;19(3):711-718.

Emicizumab initiation and bleeding outcomes in people with hemophilia A with and without inhibitors: A single-center report

Warren BB, Chan A, Manco-Johnson M, Branchford BR, et al. Res Pract Thromb Haemost. 2021 Aug 3;5(5):e12571

Modified clot waveform analysis to measure plasma coagulation potential in the presence of the anti-factor IXa/factor X bispecific antibody emicizumab

Nogami K, Matsumoto T, Tabuchi Y, et al. J Thromb Haemost 2018;16:1078–1088.

Emicizumab improves the stability and structure of fibrin clot derived from factor VIII‐deficient plasma, similar to the addition of factor VIII

Shimonishi N, Nogami K, Ogiwara K, et al. Haemophilia. 2020;26(3):e97-e105.